{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:26:37Z","timestamp":1789687597535,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":1999,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004690","name":"Minist\u00e8re de la sant\u00e9","doi-asserted-by":"publisher","award":["PHRC P040407"],"award-info":[{"award-number":["PHRC P040407"]}],"id":[{"id":"10.13039\/501100004690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004690","name":"Minist\u00e8re de la Sant\u00e9","doi-asserted-by":"publisher","award":["PHRC P040407"],"award-info":[{"award-number":["PHRC P040407"]}],"id":[{"id":"10.13039\/501100004690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypertension is a major contributor to cardiac diastolic dysfunction. Different therapeutics strategies have been proposed to control blood pressure (BP), but their independent impact on cardiac function remains undetermined. In patients with resistant hypertension, we compared the changes in cardiac parameters between two strategies based on sequential nephron blockade (NBD) with a combination of diuretics or sequential renin-angiotensin system blockade (RASB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>After a 4-week period where all patients received Irbesartan 300 mg\/day + hydrochlorothiazide 12.5 mg\/day + amlodipine 5 mg\/day, 140 resistant hypertension patients (54.8 \u00b1 11.1 years, 76% men, mean duration with hypertension: 13.1 \u00b1 10.5 years, no previous history of heart failure or current symptoms of congestive heart failure) were randomized 1:1 to the NBD regimen or to the RASB regimen at week 0 (W0, baseline). Treatment intensity was increased at week 4, 8, or 10 if home BP was \u2265135\/85 mmHg, by sequentially adding 25 mg spironolactone, 20\u201340 mg furosemide, and 5 mg amiloride (NBD group) or 5\u201310 mg ramipril and 5\u201310 mg bisoprolol (RASB group). No other antihypertensive drug was allowed during the study. BP, BNP levels, and echocardiographic parameters were assessed at weeks 0 and 12.<\/jats:p>\n                    <jats:p>The baseline characteristics, laboratory parameters, and plasma hormones (BNP, renin, and aldosterone) and cardiac echocardiographic parameters did not significantly differ between the NBD and the RASB groups. Over 12 weeks, BNP levels significantly decreased in NBD but increased in RASB (mean [CI 95%] change in log-transformed BNP levels: \u221243% [\u221267%; \u221223%] vs. +55% [46%; 62%] in NBD vs. RASB, respectively, P &amp;lt; 0.0001). Similarly, the proportion of patients presenting \u22652 echocardiographic criteria of diastolic dysfunction decreased between baseline and W12 from 31% to 3% in NBD but increased from 19% to 32% in RASB (P = 0.0048). As compared with RASB, NBD induced greater decrease in ambulatory systolic BP (P &amp;lt; 0.0001), pulse pressure (P &amp;lt; 0.0001), and systemic vascular resistance (P &amp;lt; 0.005). In multivariable linear regression analyses, NBD treatment was significantly associated with decreased BNP levels (adjusted \u00df: \u221246.41 \u00b1 6.99, P &amp;lt; 0.0001) independent of age, gender, renal function, and changes in BPs or heart rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with resistant hypertension, nephron blockade with a combination of diuretics significantly improves cardiac markers of diastolic dysfunction independently of BP lowering.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12832","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T06:57:02Z","timestamp":1593413822000},"page":"2561-2571","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Sequential Nephron Blockade with Combined Diuretics Improves Diastolic Function in Patients with Resistant Hypertension"],"prefix":"10.1093","volume":"7","author":[{"given":"David","family":"Fouassier","sequence":"first","affiliation":[{"name":"Centre d'Investigations Cliniques CIC1418, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]},{"name":"Paris Cardiovascular Research Center PARCC, INSERM, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques CIC1418, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]},{"name":"Paris Cardiovascular Research Center PARCC, INSERM, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Fayol","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques CIC1418, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]},{"name":"Paris Cardiovascular Research Center PARCC, INSERM, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Bobrie","sequence":"additional","affiliation":[{"name":"Assistance Publique H\u00f4pitaux de Paris, Hypertension unit, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Boutouyrie","sequence":"additional","affiliation":[{"name":"Paris Cardiovascular Research Center PARCC, INSERM, Universit\u00e9 de Paris , Paris ,","place":["France"]},{"name":"Assistance Publique H\u00f4pitaux de Paris, Pharmacology department, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques CIC1418, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]},{"name":"Paris Cardiovascular Research Center PARCC, INSERM, Universit\u00e9 de Paris , Paris ,","place":["France"]},{"name":"Assistance Publique H\u00f4pitaux de Paris, Hypertension unit, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Hulot*","sequence":"additional","affiliation":[{"name":"Centre d'Investigations Cliniques CIC1418, AP-HP, H\u00f4pital Europ\u00e9en Georges Pompidou , Paris ,","place":["France"]},{"name":"Paris Cardiovascular Research Center PARCC, INSERM, Universit\u00e9 de Paris , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"key":"2026012114063080100_ehf212832-bib-0001","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114063080100_ehf212832-bib-0002","doi-asserted-by":"crossref","first-page":"137","DOI":"10.14740\/jocmr2050w","article-title":"Left ventricular diastolic function in hypertension: methodological considerations and clinical implications","volume":"7","author":"Palmiero","year":"2015","journal-title":"J Clin Med Res"},{"issue":"33","key":"2026012114063080100_ehf212832-bib-0003","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESH Guidelines for th\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"European Heart Journal"},{"key":"2026012114063080100_ehf212832-bib-0004","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"2026012114063080100_ehf212832-bib-0005","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","article-title":"Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion","volume":"168","author":"Gaddam","year":"2008","journal-title":"Arch Intern Med"},{"key":"2026012114063080100_ehf212832-bib-0006","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"2026012114063080100_ehf212832-bib-0007","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1161\/CIRCRESAHA.116.302706","article-title":"Role of mineralocorticoid receptor antagonists in cardiovascular disease","volume":"116","author":"Ferrario","year":"2015","journal-title":"Circ Res"},{"key":"2026012114063080100_ehf212832-bib-0008","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamacardio.2016.1878","article-title":"Mineralocorticoid receptor antagonists in the management of heart failure and resistant hypertension: a review","volume":"1","author":"Flatt","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114063080100_ehf212832-bib-0009","doi-asserted-by":"crossref","first-page":"9556","DOI":"10.1038\/s41598-018-27799-y","article-title":"Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction","volume":"8","author":"Tsujimoto","year":"2018","journal-title":"Sci Rep"},{"key":"2026012114063080100_ehf212832-bib-0010","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"2026012114063080100_ehf212832-bib-0011","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/HJH.0000000000000280","article-title":"Greater efficacy of aldosterone blockade and diuretic reinforcement vs dual renin\u2013angiotensin blockade for left ventricular mass regression in patients with resistant hypertension","volume":"32","author":"Azizi","year":"2014","journal-title":"J Hypertens"},{"key":"2026012114063080100_ehf212832-bib-0012","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","article-title":"Recommendations for chamber quantification","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"2026012114063080100_ehf212832-bib-0013","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"Journal of the American Society of Echocardiography"},{"key":"2026012114063080100_ehf212832-bib-0014","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/clc.4960200918","article-title":"Calculating vascular resistances","volume":"20","author":"Skimming","year":"1997","journal-title":"Clin Cardiol"},{"key":"2026012114063080100_ehf212832-bib-0015","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehq165","article-title":"Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: \u2018establishing normal and reference values\u2019","volume":"31","author":"The Reference Values for Arterial Stiffness' Collaboration","year":"2010","journal-title":"Eur Heart J"},{"key":"2026012114063080100_ehf212832-bib-0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","article-title":"Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity","volume":"30","author":"Bortel","year":"2012","journal-title":"J Hypertens"},{"key":"2026012114063080100_ehf212832-bib-0017","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0895-7061(00)01245-0","article-title":"Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension","volume":"14","author":"Aeschbacher","year":"2001","journal-title":"Am J Hypertens"},{"key":"2026012114063080100_ehf212832-bib-0018","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jacc.2011.11.034","article-title":"Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension","volume":"59","author":"Brandt","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026012114063080100_ehf212832-bib-0019","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.1436","article-title":"The role of ventricular\u2013arterial coupling in cardiac disease and heart failure: assessment, clinical implications and therapeutic interventions","volume":"21","author":"Ikonomidis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012114063080100_ehf212832-bib-0020","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2015.10.084","article-title":"Pulse pressure and risk for cardiovascular events in patients with atherothrombosis: From the REACH registry","volume":"67","author":"Selvaraj","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012114063080100_ehf212832-bib-0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/MNH.0000000000000089","article-title":"Vascular effects of dietary salt","volume":"24","author":"Edwards","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012114063080100_ehf212832-bib-0022","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/ndt\/gft461","article-title":"Vascular endothelium: a vulnerable transit zone for merciless sodium","volume":"29","author":"Oberleithner","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026012114063080100_ehf212832-bib-0023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.semnephrol.2014.08.007","article-title":"Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels","volume":"34","author":"Judd","year":"2014","journal-title":"Semin Nephrol"},{"key":"2026012114063080100_ehf212832-bib-0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/HYPERTENSIONAHA.114.03348","article-title":"Endothelial sodium channels trigger endothelial salt sensitivity with aging","volume":"64","author":"Paar","year":"2014","journal-title":"Hypertension"},{"key":"2026012114063080100_ehf212832-bib-0025","doi-asserted-by":"crossref","first-page":"H2341","DOI":"10.1152\/ajpheart.01126.2011","article-title":"Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat","volume":"302","author":"Ma","year":"2012","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"2026012114063080100_ehf212832-bib-0026","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.jacc.2009.11.084","article-title":"Differential effects of antihypertensive treatment on left ventricular diastolic function","volume":"55","author":"Tapp","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114063080100_ehf212832-bib-0027","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000092766","article-title":"Bisoprolol improves echocardiographic parameters of left ventricular diastolic function in patients with systemic hypertension","volume":"106","author":"Ilgenli","year":"2006","journal-title":"Cardiology"},{"key":"2026012114063080100_ehf212832-bib-0028","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012721.pub2","article-title":"Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Heart Group, editor","author":"Martin","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026012114063080100_ehf212832-bib-0029","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"ONTARGET Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"2026012114063080100_ehf212832-bib-0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12832","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/5\/2561\/65806993\/eschf_7_5_2561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/5\/2561\/65806993\/eschf_7_5_2561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:07:06Z","timestamp":1769022426000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/5\/2561\/8372116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":30,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,6,29]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12832","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"2019-09-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}